发明授权
- 专利标题: Use of antagonistic anti-CD40 monoclonal antibodies
- 专利标题(中): 拮抗性抗CD40单克隆抗体的应用
-
申请号: EP09075395.5申请日: 2004-11-04
-
公开(公告)号: EP2149585B1公开(公告)日: 2013-08-14
- 发明人: Long, Li , Luqman, Mohammed , Yabannavar, Asha , Zaror, Isabel , Chen, Bao-Lu , Lu, Xiaofeng , Lee, Sang Hoon , Hurst, Deborah
- 申请人: Novartis Vaccines and Diagnostics, Inc.
- 申请人地址: 4560 Horton Street Emeryville, CA 94608 US
- 专利权人: Novartis Vaccines and Diagnostics, Inc.
- 当前专利权人: Novartis Vaccines and Diagnostics, Inc.
- 当前专利权人地址: 4560 Horton Street Emeryville, CA 94608 US
- 代理机构: Marshall, Cameron John
- 优先权: US517337 20031104; US525579 20031126; US565710 20040427
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61K38/20 ; A61K39/395
摘要:
Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
公开/授权文献
信息查询